Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?
作者信息
Burstein Harold J, Piccart-Gebhart Martine J, Perez Edith A, Hortobagyi Gabriel N, Wolmark Norman, Albain Kathy S, Norton Larry, Winer Eric P, Hudis Clifford A
机构信息
Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.
出版信息
J Clin Oncol. 2012 Jun 20;30(18):2179-82. doi: 10.1200/JCO.2012.42.0695. Epub 2012 May 21.
Abstract
摘要
相似文献
1
Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?
J Clin Oncol. 2012 Jun 20;30(18):2179-82. doi: 10.1200/JCO.2012.42.0695. Epub 2012 May 21.
2
Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer.
J Natl Cancer Inst. 2013 Jun 19;105(12):835-6. doi: 10.1093/jnci/djt161. Epub 2013 Jun 2.
3
Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
J Clin Oncol. 2015 Apr 1;33(10):1136-42. doi: 10.1200/JCO.2014.58.7782. Epub 2015 Feb 23.
4
Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials.
Med Oncol. 2014 Dec;31(12):340. doi: 10.1007/s12032-014-0340-x. Epub 2014 Nov 22.
5
Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
J Natl Cancer Inst. 2009 Apr 1;101(7):448-9. doi: 10.1093/jnci/djp072. Epub 2009 Mar 24.
6
Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Clin Adv Hematol Oncol. 2008 Sep;6(9):666-72.
7
Ongoing debate: anthracyclines and adjuvant treatment of human epidermal growth factor receptor 2-positive breast cancer.
J Clin Oncol. 2012 Dec 10;30(35):4445-6; author reply 4446. doi: 10.1200/JCO.2012.44.9991. Epub 2012 Oct 15.
8
Adjuvant anthracyclines: time for a change of heart?
Oncology (Williston Park). 2011 Feb;25(2):140, 142.
9
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
J Natl Cancer Inst. 2012 Sep 5;104(17):1293-305. doi: 10.1093/jnci/djs317.
10
[HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
Bull Cancer. 2006 Oct;93(10):991-9.
引用本文的文献
1
A Decade of AGO QS-Mamma: Adherence to the Recommendations of the AGO Breast Committee for Diagnosis and Treatment in EBC in Routine Therapy in Germany.
Breast Care (Basel). 2025 Apr;20(2):66-74. doi: 10.1159/000543237. Epub 2025 Jan 21.
2
Decision Science Can Inform Clinical Trade-Offs Regarding Cardiotoxic Cancer Treatments.
JNCI Cancer Spectr. 2021 Jun 24;5(4). doi: 10.1093/jncics/pkab053. eCollection 2021 Aug.
3
The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.
Am J Cancer Res. 2020 Apr 1;10(4):1045-1067. eCollection 2020.
4
Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
Int J Clin Oncol. 2019 Jul;24(7):807-814. doi: 10.1007/s10147-019-01420-2. Epub 2019 Feb 27.
5
Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review.
Curr Treat Options Oncol. 2018 May 11;19(6):30. doi: 10.1007/s11864-018-0547-8.
6
Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Breast Cancer Res Treat. 2017 Nov;166(1):241-247. doi: 10.1007/s10549-017-4362-x. Epub 2017 Jul 14.
7
Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Oncologist. 2017 Jun;22(6):642-647. doi: 10.1634/theoncologist.2016-0406. Epub 2017 Mar 24.
8
Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany.
Oncologist. 2017 Feb;22(2):131-138. doi: 10.1634/theoncologist.2016-0193. Epub 2017 Feb 7.
9
Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer.
Breast Cancer Res Treat. 2016 May;157(1):145-56. doi: 10.1007/s10549-016-3790-3. Epub 2016 Apr 23.
10
Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice.
Springerplus. 2016 Mar 31;5:395. doi: 10.1186/s40064-016-2008-9. eCollection 2016.
本文引用的文献
1
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
J Clin Oncol. 2011 Dec 1;29(34):4491-7. doi: 10.1200/JCO.2011.36.7045. Epub 2011 Oct 31.
2
Adjuvant trastuzumab in HER2-positive breast cancer.
N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.
3
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.
Cancer. 2012 May 1;118(9):2385-93. doi: 10.1002/cncr.26555. Epub 2011 Sep 27.
4
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
J Clin Oncol. 2011 Sep 1;29(25):3366-73. doi: 10.1200/JCO.2011.35.0868. Epub 2011 Jul 18.
5
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
Clin Cancer Res. 2011 May 15;17(10):3490-9. doi: 10.1158/1078-0432.CCR-10-1359. Epub 2011 Mar 3.
6
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Lancet Oncol. 2011 Mar;12(3):236-44. doi: 10.1016/S1470-2045(11)70033-X. Epub 2011 Feb 25.
7
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
J Clin Oncol. 2011 Mar 1;29(7):859-67. doi: 10.1200/JCO.2009.27.5644. Epub 2010 Dec 28.
8
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
J Clin Oncol. 2011 Jan 10;29(2):149-56. doi: 10.1200/JCO.2010.28.6450. Epub 2010 Nov 29.
9
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Lancet. 2010 Jan 30;375(9712):377-84. doi: 10.1016/S0140-6736(09)61964-4.
10
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
J Clin Oncol. 2009 Dec 20;27(36):6129-34. doi: 10.1200/JCO.2009.23.0946. Epub 2009 Nov 16.
Zotero 插件